Infectious Disorders
Acute flaccid myelitis
Aug. 26, 2024
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.
mRNA expression in mononuclear white blood cells in multiple sclerosis shows massive gene dysregulation and correction by long-term IFN-beta therapy. A. Partial responders (PR) to IFN-beta therapy, while clinically stable, 4 days after last injection vs. untreated multiple sclerosis during exacerbations (left) and vs. untreated multiple sclerosis while stable (right). B. Untreated stable multiple sclerosis vs. healthy controls (HC) (left) and stable PR after 4-day washout vs. HC (right). (Adapted from:Feng X, Bao R, Li L, Deisenhammer F, Arnason BGW, Reder AT. Interferon-β corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection. EBioMedicine 2019;49:69-283.)